A meta-analysis of nine RCTs also reported lower risk of hypoglycaemia with SGLT2 inhibitors (OR 0.48; 95% CI 0.28, 0.82; p = 0.008) [38]. Here, SLC5A2 is linked to Hypoglycemia.